<DOC>
	<DOCNO>NCT02413320</DOCNO>
	<brief_summary>Evaluate two carboplatin contain chemotherapy regimen reduce growth breast cancer cell woman Stage I , II , III triple negative breast cancer .</brief_summary>
	<brief_title>Neoadjuvant Study Two Platinum Regimens Triple Negative Breast Cancer</brief_title>
	<detailed_description>Sporadic germline BRCA mutation associate triple-negative breast cancer share several pathological molecular similarity lead exploration DNA damaging agent like platinum compound patient triple-negative breast cancer . Recent study demonstrate addition neoadjuvant carboplatin doxorubicin/cyclophosphamide/taxane-based chemotherapy improve pathological complete response patient stage I-III triple-negative breast cancer also increase toxicity . A recent study report encouraging pathological complete response rate non-anthracycline carboplatin plus docetaxel neoadjuvant chemotherapy regimen cohort 49 triple negative breast cancer patient . This chemotherapy regimen carboplatin plus docetaxel yield overall pathological complete response rate 65 % unselected triple-negative breast cancer pathological complete response rate 61 % sporadic 77 % germline BRCA-associated triple-negative breast cancer . The chemotherapy regimen carboplatin/docetaxel well tolerate study compare regimen add carboplatin standard anthracycline/taxane contain regimen . This basis propose randomize neoadjuvant phase II study estimate compare pathological complete response rate carboplatin plus docetaxel x 6 cycle carboplatin plus paclitaxel x 4 cycle follow doxorubicin plus cyclophosphamide x 4 cycle stage I-III triple negative-breast cancer .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Triple Negative Breast Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<criteria>Patients newly diagnose stage I ( T &gt; 1cm ) , II III triple negative breast cancer definitive breast surgery receive systemic chemotherapy The invasive tumor must hormone receptorpoor , define estrogen receptor progesterone receptor stain present ≤ 10 % invasive cancer cell Immunohistochemistry . HER 2 negativity base current ASCOCAP guideline HER test No prior chemotherapy , endocrine therapy radiation therapy therapeutic intent cancer Female subject age 18 70 year ECOG Performance Status 01 Adequate organ marrow function define : Leukocytes ≥ 3,000/uL Absolute neutrophil count ≥ 1500/uL Platelets ≥ 100,000/uL Total bilirubin ≤ 1.5mg/dL AST ( SGOT ) /ALT ( SPGT ) ≤ 2 x institutional upper limit normal Creatinine ≤ 1.5mg/dl and/or Creatinine Clearance ≥ 60mL/min Serum albumin ≥ 3.0 g/dL Women childbearing potential must agree use adequate contraception Pretreatment lab value must perform within 14 day treatment initiation , baseline study perform within 30 day prior registration Subjects LVEF ≥ 50 % echocardiogram MUGA scan perform within 4 week prior treatment initiation Subjects breast axillary imaging breast MRI breast axillary ultrasound within 4 week prior treatment initiation Subjects clinically/radiologically abnormal axillary lymph node pathological confirmation disease image guide biopsy/fine needle aspiration . Subjects must already enrol P.R.O.G.E.C.T observational registry Staging rule metastatic disease recommend subject clinical stage III disease Subjects bilateral disease eligible meet eligibility criterion . Neuropathy : No baseline neuropathy grade &gt; 2 Current anticipate use investigational agent Subject receive chemotherapy , radiotherapy surgery treatment breast cancer Subject metastatic disease History allergic reaction compound similar chemical biologic composition carboplatin , docetaxel , doxorubicin , cyclophosphamide , paclitaxel , agent use study Subjects inflammatory breast cancer Uncontrolled intercurrent illness include , limited ongoing active infection psychiatric illness/social situation would limit compliance study requirement Subject pregnant nursing Subjects concomitant previous malignancy within last 5 year . Exceptions include : adequately treat basal squamous cell carcinoma skin , carcinoma situ cervix , ductal carcinoma situ ( DCIS ) . Ejection Fraction &lt; 50 % ECHO MUGA Cardiac function : Subjects congestive heart failure , myocardial infarction , unstable angina pectoris , arterial thrombotic event , stroke transient ischemia attack within past 12 month , uncontrolled hypertension ( Systolic BP &gt; 160 Diastolic BP &gt; 90 ) , uncontrolled symptomatic arrhythmia , grade ≥ 2 peripheral vascular disease</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>TNBC , breast cancer , neoadjuvant , carboplatin , docetaxel , paclitaxel , doxorubicin , cyclophosphamide</keyword>
</DOC>